TACC3 and neoplasm: In vaccine trials, in vivo inhibition of TACC3 triggered immunogenic cell death and enhanced the anti-tumor efficacy of T-DM1 by inducing dendritic cell maturation and increasing cytotoxic T-cell infiltration into the tumor microenvironment [34].